Abida W et al. Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2020;Abstract 178.
Abida W et al. Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses. ESMO 2019;Abstract 846PD.
Agarwal N et al. TALAPRO-2: A placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2020;Abstract TPS264.
Agarwal N et al. Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC). ASCO 2019;Abstract 5076.
Arce S et al. Germline and somatic defects in DNA repair pathways in prostate cancer. Adv Exp Med Biol 2019;1210:279-300. Abstract
Chi KN et al. A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641). Genitourinary Cancers Symposium 2020;Abstract TPS257.
Clarke NW et al. PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2019;Abstract TPS340.
De Bono JS et al. TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC) — First interim analysis (IA). Genitourinary Cancers Symposium 2020;Abstract 119.
De Bono JS et al. Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. ESMO 2019;Abstract 847PD.
Fraser M et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 2017;541(7637):359-64. Abstract
Hussain M et al. PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. ESMO 2019;Abstract LBA12_PR.
Hussain M et al. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: Results from NCI 9012. J Clin Oncol 2018;36(10):991-9. Abstract
LaFargue CJ et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 2019;20(1):e15-28. Abstract
Marshall CH et al. Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: Association of Gleason score and tumor stage. Prostate Cancer Prostatic Dis 2019;22(1):59-65. Abstract
Marshall CH et al. Response to PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with BRCA1/2 versus ATM mutations. Genitourinary Cancers Symposium 2019;Abstract 154.
Mateo J et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): A multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020;21(1):162-74. Abstract
Mateo J et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015;373(18):1697-708. Abstract
Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther 2017;10:5195-208. Abstract
Paller CJ et al; PCCTC Germline Genetics Working Group. Germline genetic testing in advanced prostate cancer; practices and barriers: Survey results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clin Genitourin Cancer 2019;17(4):275-82.e1. Abstract
Phase II trial of rucaparib in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations (TRIUMPH). NCT03413995
Pomerantz MM et al. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer 2017;123(18):3532-9. Abstract
Pritchard CC et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016;375(5):443-53. Abstract
Ryan CJ et al. TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Genitourinary Cancers Symposium 2018;Abstract TPS389.
Shenderov E et al. Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype. Prostate 2019;79(13):1572-9. Abstract
Smith MR et al. Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study. Genitourinary Cancers Symposium 2020;Abstract 118.
Smith MR et al. Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD). ESMO 2019;Abstract LBA50.
Sternberg CN et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. J Clin Oncol 2009;27(32):5431-8. Abstract
VanderWeele DJ et al. Metastatic hormone-sensitive prostate cancer: Clinical decision making in a rapidly evolving landscape of life-prolonging therapy. J Clin Oncol 2019;37(32):2961-7. Abstract
Yu EY et al. Phase III study of pembrolizumab (pembro) plus olaparib versus enzalutamide (enza) or abiraterone acetate (abi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed on chemotherapy: KEYLYNK-010. Genitourinary Cancers Symposium 2020;Abstract TPS256.